Clinical Trials Logo

Advanced Solid Tumour clinical trials

View clinical trials related to Advanced Solid Tumour.

Filter by:
  • None
  • Page 1

NCT ID: NCT05109650 Terminated - Clinical trials for Advanced Solid Tumour

Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients

Start date: November 15, 2021
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, Phase 1 dose-escalation study of BAT6026, an OX40 monoclonal antibody, combined with the anti-PD-1 IgG4 monoclonal antibody BAT1308 in subjects with advanced solid tumours. After a screening period of up to 28 days, qualified subjects will be enrolled to receive their assigned dose regimen until disease progression or intolerable toxicity, withdrawal of consent, per Investigator decision, or end of study, whichever occurs first. The maximum treatment duration is 1 year. Subjects who remain on treatment in the absence of disease progression for more than 1 year may continue to receive study drug for the next cycle at the maximum of 2 years.